Steward Partners Investment Advisory LLC Boosts Stake in Insulet Co. (NASDAQ:PODD)

Steward Partners Investment Advisory LLC grew its holdings in Insulet Co. (NASDAQ:PODDFree Report) by 20.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,201 shares of the medical instruments supplier’s stock after purchasing an additional 202 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Insulet were worth $261,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Baillie Gifford & Co. purchased a new position in Insulet during the fourth quarter worth about $263,144,000. Norges Bank purchased a new position in shares of Insulet during the 4th quarter worth approximately $227,655,000. William Blair Investment Management LLC boosted its position in shares of Insulet by 145.1% during the 3rd quarter. William Blair Investment Management LLC now owns 732,923 shares of the medical instruments supplier’s stock worth $116,894,000 after purchasing an additional 433,884 shares during the period. Qube Research & Technologies Ltd increased its holdings in Insulet by 227.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 386,687 shares of the medical instruments supplier’s stock valued at $61,673,000 after purchasing an additional 268,553 shares during the last quarter. Finally, Westfield Capital Management Co. LP raised its position in Insulet by 62.4% in the third quarter. Westfield Capital Management Co. LP now owns 637,261 shares of the medical instruments supplier’s stock valued at $101,637,000 after purchasing an additional 244,922 shares during the period.

Insider Buying and Selling at Insulet

In other news, Director Timothy J. Scannell sold 3,300 shares of the business’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $180.90, for a total value of $596,970.00. Following the completion of the sale, the director now directly owns 42,586 shares of the company’s stock, valued at approximately $7,703,807.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.47% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Wolfe Research upgraded Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price target for the company in a research report on Tuesday, May 7th. Jefferies Financial Group lifted their target price on Insulet from $255.00 to $260.00 and gave the company a “buy” rating in a research report on Friday, May 10th. JPMorgan Chase & Co. increased their price target on shares of Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Raymond James lowered their price objective on shares of Insulet from $218.00 to $213.00 and set an “outperform” rating for the company in a research note on Friday, May 10th. Finally, Redburn Atlantic began coverage on shares of Insulet in a research note on Thursday, May 30th. They set a “buy” rating and a $235.00 target price on the stock. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, Insulet currently has a consensus rating of “Moderate Buy” and an average target price of $239.18.

View Our Latest Research Report on PODD

Insulet Price Performance

Shares of NASDAQ PODD opened at $191.42 on Friday. The stock’s 50-day simple moving average is $174.44 and its 200-day simple moving average is $185.42. The company has a debt-to-equity ratio of 1.72, a quick ratio of 2.75 and a current ratio of 3.74. The firm has a market capitalization of $13.41 billion, a PE ratio of 58.01, a price-to-earnings-growth ratio of 3.46 and a beta of 1.14. Insulet Co. has a fifty-two week low of $125.82 and a fifty-two week high of $298.95.

Insulet (NASDAQ:PODDGet Free Report) last issued its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.34. The business had revenue of $441.70 million during the quarter, compared to the consensus estimate of $424.05 million. Insulet had a net margin of 13.14% and a return on equity of 34.06%. The company’s revenue was up 23.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.23 EPS. As a group, equities research analysts forecast that Insulet Co. will post 3.11 EPS for the current fiscal year.

Insulet Company Profile

(Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Recommended Stories

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODDFree Report).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.